INOVIO is powering DNA medicines through collaborations with industry, academia, and government.

Our partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Defense Advanced Research Projects Agency (DARPA)/Department of Defense (DOD), Geneos Therapeutics, International Vaccine Institute (IVI), Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, The Wistar Institute, and the World Health Organization (WHO).

We or our collaborators are currently conducting or planning clinical studies of our DNA medicines for HPV-associated diseases, such as recurrent respiratory papillomatosis (RRP); glioblastoma multiforme (GBM); Ebola; and COVID-19 (coronavirus).